Effect of withdrawal of fusafungine from the market on prescribing of antibiotics and other alternative treatments in Germany: a pharmacovigilance impact study

Karin Hedenmalm1,2 • Xavier Kurz3 • Daniel Morales3

Received: 3 October 2018 / Accepted: 15 February 2019 © The Author(s) 2019

Abstract

Purpose Knowledge on unintended consequences of product withdrawals is limited. Fusafungine, indicated for treatment of upper respiratory airways disease (URAD), was withdrawn in the EU on May 28, 2016. Given concerns about possible substitution with antibiotics, this study aimed to assess the impact of the withdrawal of fusafungine on prescribing of antibiotics and other treatments.

Methods The study was conducted using data from general practitioner (GP) and ear, nose and throat (ENT) practices in IMS® Disease Analyzer Germany. The quarterly prevalence of fusafungine prescribing was analysed for consultations involving the most common URAD between May 29, 2013 and May 28, 2017 in regular fusafungine-prescribing practices. Trends in the quarterly prevalence of antibiotics (AB), other nasal or throat preparations (N&T) and tyrothricin were analyzed. Practices with no fusafungine prescribing during the study served as controls. Changes in prescribing trend were evaluated using interrupted time series regression analysis.

Results In fusafungine-prescribing practices, withdrawal of fusafungine was associated with an immediate increase in prescribing of other N&Ts among patients consulting for URAD (+ 6.4%, 95% CI 2.3–10.5% in GP practices and + 9.0%, 95% CI 5.5–12.5% in ENT practices). There was no increase in antibiotic prescribing. In ENT practices; a small transient increase in tyrothricin prescribing occurred. No changes were seen in non-fusafungine-prescribing practices.

Conclusions Withdrawal of fusafungine was not associated with increased prescribing of antibiotics but was associated with increased prescribing of other N&Ts. The unintended impact of substitution to other treatments should be considered routinely when products are withdrawn or restricted in other ways.

Keywords Fusafungine • Upper respiratory airways disease • Antibiotics • Alternative prescribing

Introduction

Fusafungine is an antimicrobial and anti-inflammatory agent administered via inhalation into the nostrils or orally. It was authorised in 19 European Union (EU) member states for local antibacterial and anti-inflammatory treatment of upper respiratory airways disease (URAD), including sinusitis, rhinitis, rhinopharyngitis, angina, laryngitis and tracheitis [1]. Fusafungine consists of a mixture of enniatins [2] and has been widely used over the past 50 years [1]. Its first authorisation in the EU was in 1963. Fusafungine has multiple mechanisms of action, including downregulation of the expression of intercellular adhesion molecule-1 (ICAM-1) and inhibition of production of proinflammatory cytokines [3]. In September 2015, an EU-wide assessment of the benefit-risk of fusafungine was initiated due to an increase in the reporting
rate of serious allergic reactions [4], estimated at a rate of 0.17 cases per 100,000 canisters [1]. In February 2016, the European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) recommended that fusafungine should be withdrawn from the EU market, and this recommendation was implemented with immediate effect on 28 May 2016 [5, 6]. In addition to the risk of serious allergic reactions, contributing factors to the withdrawal decision included the lack of evidence around efficacy/effectiveness and the inability to exclude the risk of antimicrobial resistance [1, 6].

Medicinal products are removed from the market due to unfavorable benefit-risk profiles. However, these decisions might lead to substitutions to alternative medicines that are not always necessary, safer or more effective. The aim of this study was to estimate the impact of the market withdrawal of fusafungine in Germany on potential alternative treatments including antibiotics, locally acting antimicrobials and other nasal or throat preparations for the management of URAD.

Methods

Data source

Germany was selected for the study due to a high rate of prescriptions for fusafungine [7], whereas in some other EU countries (e.g. France and the United Kingdom) fusafungine was not available on the market. The study used data from the IMS® Disease Analyzer Germany, version June 2017. IMS® Disease Analyzer Germany contains anonymised medical records from a representative panel of general practitioners (GPs), specialists in internal medicine and other specialist physicians in computerized practices throughout Germany since 1992 [8]. Primary care data from Germany contains data on diagnoses, prescriptions, and risk factors such as smoking or obesity, referrals and sick notes and test results. In Germany, patients are not required to register with a GP to be referred to a specialist physician.

Study design

A time series study design was used to measure the impact of fusafungine withdrawal among patients seeking consultation for URAD. The study observation period was from 29 May 2013 to 28 May 2017. Practices included in the study were required to have continuous data delivery between May 2013 and June 2017. The study included data from GPs and ear, nose and throat (ENT) specialists capturing 98.6% of all fusafungine prescriptions.

Indication for treatment

Consultations for the most commonly occurring URAD conditions were defined by screening and ranking clinical diagnoses recorded on the same day as fusafungine in order of frequency. The three most common diagnoses that were selected and included for GP practices were acute pharyngitis (ICD code J02.9), acute upper airways infection (ICD code J06.9) and acute laryngitis (ICD code J04.0), and for ENT practices, they were acute laryngitis (ICD code J04.0), acute pharyngitis (ICD code J02.9) and acute laryngopharyngitis (ICD code J06.0).

Fusafungine-prescribing practices

Trends in prescribing were compared between regular fusafungine-prescribing practices and non-fusafungine-prescribing practices. Regular fusafungine-prescribing practices were defined as practices having at least 0.5% of all patients prescribed fusafungine, and at least 5% of patients consulting for URAD, in each year for 3 years prior to the withdrawal of fusafungine. GP and ENT practices with no fusafungine prescribing in the same period were then selected as a control group.

Exposures

Four types of exposure were analyzed: prescriptions for fusafungine-containing products, prescriptions for systemic antibiotics, prescriptions for other locally acting antimicrobials besides fusafungine, i.e. tyrothricin-containing products and prescriptions for other nasal or throat preparations (N&Ts). Fusafungine- and tyrothricin-containing products were identified by substance name belonging to the EphMRA ATC code R01A4 (nasal anti-infectives without corticosteroids) and R02A0 (throat preparations) respectively. Other N&Ts were identified by EphMRA ATC codes: R01A topical nasal preparations, R01B systemic nasal preparations and R02A throat preparations, excluding products containing fusafungine or tyrothricin. Systemic antibiotics were identified by the following EphMRA ATC codes: J01A tetracyclines and combinations, J01B chloramphenicol and combinations, J01C broad-spectrum penicillins, J01D cephalosporins, J01E trimethoprim and similar preparations, J01F macrolides and similar types, J01G fluoroquinolones, J01H plain medium and narrow spectrum penicillins and penicillin/streptomycin combinations, J01K aminoglycosides, J01L carbenicillin and similar types, J01P other beta-lactam antibacterials excluding penicillins and cephalosporins and J01X other antibacterials.
Analysis

Among patients consulting for URAD, trends in the following treatments were examined over the study period using quarterly time intervals: (1) treatment with systemic antibiotics, (2) treatment with fusafungine, (3) treatment with tyrothricin, (4) treatment with other N&T, and (5) no treatment. The treatments were defined as mutually exclusive groups. Quarterly time intervals were defined from 29 May to 28 August, 29 August to 28 November, 29 November to 28 February and 29 February/1 March to 28 May for each year. Interrupted time series regression analysis was chosen to statistically evaluate the effect of the withdrawal [9]. Using linear regression analysis, the immediate impact of the withdrawal and any change in subsequent trends in prescribing was compared between the 12 pre-intervention quarters and the 4 post-intervention quarters [10]. Autocorrelation was evaluated using the Durbin Watson test [11–13]. Analysis was conducted using SAS Enterprise Guide version 7.13. All analyses were performed by the authors based on IMS® Disease Analyzer Germany.

Results

A total of 31 GP (3.0%) and 17 ENT (15.5%) regular fusafungine-prescribing practices were identified, within which 4644 GP patients (3.8%) and 7527 ENT patients (3.4%) were prescribed fusafungine during the study period. Of these patients, 64.2% of GP patients and 64.6% of ENT patients had a concomitant diagnosis of URAD identified. In GP practices, the most common URAD diagnosis was upper airways infection, followed by acute pharyngitis, acute laryngitis and acute laryngopharyngitis. In ENT practices, the most common URADs were acute pharyngitis, acute laryngitis, acute laryngopharyngitis and upper airways infection. The distribution of diagnoses was similar in regular fusafungine-prescribing practices compared to non-fusafungine-prescribing practices (Supplementary material, Table A1).

Prescribing trends in URAD

Regular fusafungine-prescribing GP and ENT practices

Trends in the quarterly prevalence of prescribing of each treatment for URAD are shown in Fig. 1. for both regular fusafungine-prescribing practices and non-fusafungine-prescribing control practices. Among regular fusafungine-prescribing GP practices, the quarterly prevalence of fusafungine prescribing immediately fell in the quarter following the date of withdrawal (immediate change −7.8%, 95% CI −11.8 to −3.7%) (Table 1). Among regular fusafungine-prescribing ENT practices, the quarterly prevalence of fusafungine prescribing also immediately fell in the quarter following the date of withdrawal (immediate change −13.7%, 95% CI −17.3 to −10.1%).

Among regular fusafungine-prescribing GP practices, the quarterly prevalence of other N&T prescribing immediately rose in the quarter following the date of withdrawal (immediate change 6.4%, 95% CI 2.3 to 10.5%) with no significant change in trend compared to the pre-intervention trend. Among regular fusafungine-prescribing ENT practices, the quarterly prevalence of other N&T prescribing also immediately rose in the quarter following the date of withdrawal (immediate change 9.0%, 95% CI 5.5 to 12.5%) with no significant change in trend compared to the pre-intervention trend.

Fusafungine withdrawal was associated with a small significant immediate increase in tyrothricin prescribing in regular fusafungine-prescribing ENT practices only (immediate change 1.7%, 95% CI 1.3 to 2.2%), with a significant decrease in trend compared to the pre-intervention trend (−0.3%, 95% CI −0.5 to −0.2%). In both GP and ENT regular fusafungine-prescribing practices, there was no significant immediate increase or change in trend in systemic antibiotic prescribing associated with fusafungine withdrawal.

Non-fusafungine-prescribing control practices

Fusafungine withdrawal was not associated with any significant changes in prescribing of systemic antibiotics, tyrothricin or other N&T in non-fusafungine-prescribing GP or ENT control practices.

Discussion

Electronic health records provide an important means to study the impact of medicines regulatory interventions on prescribing behaviour. Our study found that in regular fusafungine prescribing GP and ENT practices in Germany, the withdrawal of fusafungine was associated with an immediate change in health care professional behaviour with increased prescribing of other N&T products for URAD. In this regard, there was no significant change in the proportion of untreated patients, an effect similarly noted in other interventions resulting in changing antibacterial guideline recommendations [14]. Importantly, we observed no statistically significant increase in prescribing of systemic antibiotics and only a small temporary increase in prescribing of tyrothricin-containing products from ENT practices, which is reassuring in terms of the risk of antibiotic resistance and other antibiotic-related adverse drug reactions that may have occurred. In this regard, a decreased prescribing of systemic antibiotics due to treatment with fusafungine has been reported in France [15, 16], and consequently an increase in prescribing of systemic antibiotics after withdrawal of fusafungine may have been expected.
The most common other N&Ts in fusafungine-prescribing practices during the study period included mometasone (21.6%), xylometazoline (14.2%), xylometazoline in combination with dexpanthenol (10.1%) and multisubstance preparations (9.7%). These substances may carry their own risks, for example xylometazoline could cause sympathomimetic adverse reactions \[17-20\], and mometasone could cause adrenal suppression if significant systemic absorption occurs when used in high doses over long periods of time \[21-23\].

Long-term use of nasal decongestants such as xylometazoline is also associated with a risk of development of rhinitis medicamentosa \[24\]. Hence, it is unknown to what extent the discontinuation of fusafungine and subsequent change in health care professional behaviour with increased prescribing of other N&Ts has actually resulted in an improved overall net-benefit risk balance for patients.

Although the findings are reassuring, our study suggests that it is important to follow up on the consequences of regulatory interventions leading to the withdrawal of medicinal products from the market and to ascertain the extent to which substitution by alternative treatments occur, particularly in cases where alternative treatment options may themselves confer other risks. The effects of other measures of drug restrictions, not limited to regulatory actions, could also be studied using the same methods. In this regard, a recent systematic review of studies measuring the impact of regulatory interventions found that examining unintended consequences of regulatory decisions, such as substitutions and spill-over effects, was infrequently performed after implementation of regulatory actions \[25\].

This study has some potential limitations. Firstly, the interrupted time series regression approach only examines temporal associations which may be influenced by other factors if occurring during the same time. However, the absence of an effect within the control practices (non-fusafungine prescribing) provides further evidence that the observed effects are indeed related to the withdrawal of fusafungine.

The dark grey bar indicates the last quarter when fusafungine could still be prescribed. Treatment pathways: None, no treatment; NT, treatment with other nasal and throat preparations (not containing fusafungine and tyrothricin) alone; Tyrothricin, treatment with tyrothricin but no treatment with systemic antibiotics or fusafungine; Fusafungine, treatment with fusafungine but no treatment with systemic antibiotics, and AB, treatment with systemic antibiotics. URAD: acute pharyngitis (ICD code J02.9), acute laryngitis (ICD code J04.0), acute laryngopharyngitis (ICD code J06.0) or upper airways infection (ICD code J06.9). Own calculations, based on IMS® Disease Analyzer Germany.
Interrupted time series analysis of changes in prescribing of alternative treatments for upper respiratory airways disease (URAD) after withdrawal of fusafungine. Significant changes (p < 0.05) are shown in italic. AB treatment with systemic antibiotics, CL confidence limits, ENT ear, nose and throat, GP general practitioner, Fusafungine treatment with fusafungine but not systemic antibiotics, Other N&T treatment with other nasal and throat preparations not containing fusafungine or tyrothricin alone, Tyrothricin treatment with tyrothricin but not fusafungine or systemic antibiotics, URAD acute pharyngitis (ICD code J02.9), acute laryngitis (ICD code J04.0), acute laryngopharyngitis (ICD code J06.0) or upper airways infection (ICD code J06.9). Own calculations, based on IMS® Disease Analyzer Germany

<table>
<thead>
<tr>
<th>Type of practice</th>
<th>Alternative treatment</th>
<th>Immediate change in prescribing in percent (95% CL) after withdrawal of fusafungine</th>
<th>Control practices²</th>
<th>Fusafungine-prescribing practices¹</th>
<th>Control practices²</th>
<th>Change in trend in prescribing in percent (95% CL) after withdrawal of fusafungine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GP</td>
<td>No treatment</td>
<td>−1.5% (−11.2%; 8.2%)</td>
<td>−2.4% (−7.8%; 3.1%)</td>
<td>0.3% (−3.0%; 3.6%)</td>
<td>0.0% (−1.9%; 1.8%)</td>
<td></td>
</tr>
<tr>
<td>Other N&amp;T</td>
<td>6.4% (2.3%; 10.5%)</td>
<td>0.7% (−0.7%; 2.1%)</td>
<td>−0.2% (−0.5%; 0.0%)</td>
<td>0.5% (−0.9%; 1.9%)</td>
<td>0.0% (−0.7%; 0.3%)</td>
<td></td>
</tr>
<tr>
<td>Tyrothricin</td>
<td>0.3% (−0.5%; 1.1%)</td>
<td>−0.0% (−0.4%; 0.3%)</td>
<td>−0.2% (−0.5%; 0.0%)</td>
<td>0.0% (−0.0%; 0.1%)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Fusafungine</td>
<td>−7.8% (−11.8%; −3.7%)</td>
<td>NA</td>
<td>−0.0% (−1.4%; 1.4%)</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>AB</td>
<td>2.5% (−3.3%; 8.4%)</td>
<td>1.7% (−3.1%; 6.6%)</td>
<td>−0.6% (−2.6%; 1.4%)</td>
<td>0.2% (−1.4%; 1.9%)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>ENT</td>
<td>No treatment</td>
<td>1.1% (−2.6%; 4.7%)</td>
<td>6.6% (−0.6%; 13.8%)</td>
<td>0.3% (−0.9%; 1.6%)</td>
<td>−1.5% (−3.9%; 1.0%)</td>
<td></td>
</tr>
<tr>
<td>Other N&amp;T</td>
<td>9.0% (5.5%; 12.5%)</td>
<td>−1.1% (−4.8%; 2.7%)</td>
<td>0.1% (−1.1%; 1.3%)</td>
<td>−0.3% (−1.6%; 0.9%)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Tyrothricin</td>
<td>1.7% (1.3%; 2.2%)</td>
<td>−0.0% (−0.1%; 0.0%)</td>
<td>−0.3% (−0.5%; 0.2%)</td>
<td>0.0% (−0.0%; 0.0%)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Fusafungine</td>
<td>−13.7% (−17.3%; −10.1%)</td>
<td>NA</td>
<td>−0.3% (−1.5%; 1.0%)</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>AB</td>
<td>1.8% (−4.1%; 7.7%)</td>
<td>−5.5% (−11.1%; 0.0%)</td>
<td>0.2% (−1.8%; 2.2%)</td>
<td>1.8% (−0.1%; 3.7%)</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

¹ Practices with a minimum level of prescribing of fusafungine: ≥ 0.5% of all patients and ≥ 5% of patients with a selected diagnosis were prescribed fusafungine during each of the 3 years prior to the withdrawal of fusafungine (31 GP practices and 17 ENT practices)

² Practices with no prescribing of fusafungine during the 3 years prior to the withdrawal of fusafungine (291 GP practices and 17 ENT practices)

Compliance with ethical standards

Conflict of interest  The authors declare that they have no conflict of interest.

Disclaimer  The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher's note  Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

5. European Medicines Agency (2016) Timetable for the implementation of the CMDh position. European Medicines Agency, London, United Kingdom